FDA

Latest News


Latest Videos


Shorts

DIA 2026: FDA's New Stance, Quality by Design in Clinical Trials
0:28
DIA 2026: FDA's New Stance, Quality by Design in Clinical Trials
5 months ago
by
Kevin Bugin(+1 more)
Bringing Together Modern Infrastructure to Meet New FDA Standards
0:51
Bringing Together Modern Infrastructure to Meet New FDA Standards
5 months ago
by
Raj Indupuri(+1 more)
ACT Ops Take: Understanding the FDA's CNPV Program and Review Timelines
1:15
ACT Ops Take: Understanding the FDA's CNPV Program and Review Timelines
5 months ago
by
Andy Studna, Senior Editor
A Major Shift in FDA Approval for Rare Disease Therapies
0:51
A Major Shift in FDA Approval for Rare Disease Therapies
7 months ago
by
Mwango Kashoki, MD, MPH(+1 more)
ACT Ops Take: FDA Actions Reshaping Drug Development in 2026
0:59
ACT Ops Take: FDA Actions Reshaping Drug Development in 2026
8 months ago
by
Andy Studna, Senior Editor
The Shift from Frequentist to Bayesian Mindsets
0:48
The Shift from Frequentist to Bayesian Mindsets
8 months ago
by
David Morton, PhD(+1 more)
ACT Ops Take: How Bayesian Methods Revolutionize Rare Disease Trials
1:30
ACT Ops Take: How Bayesian Methods Revolutionize Rare Disease Trials
8 months ago
by
Andy Studna, Senior Editor
How FDA Uncertainty is Changing Regulatory Strategy
0:46
How FDA Uncertainty is Changing Regulatory Strategy
10 months ago
by
Charlie Paterson(+1 more)

More News

© putilov_denis - © putilov_denis - stock.adobe.com

Real-time clinical trials require standardized digital data capture at the point of care through scaled eSource-EDC-EHR integration, but progress stalls because competing standards lack regulatory enforcement and one-off system integrations cannot scale beyond single studies without industry-wide alignment and legal clarity on data ownership.

In this Q&A, Richard Graham, PhD, co-founder and chairman of the board at TruTechnologies, discusses why six decades of manual site-level processes continue to undermine clinical trial execution, what national initiatives like Operation TrialBlazer leave unaddressed, and why meaningful modernization has to start with data collected at the point of care.